”Vi måste säkerställa att alla medborgare får tillgång till nya behandlingar”

Idag är behandlingar som gavs för två år sedan redan obsoleta och inget tyder på att vi nått en platå vad gäller nya terapier. Det anser Läkemedelsverkets gener...

Uppsalabolag köper brittiskt företag i miljardaffär – och får nya storägare

Bioteknikbolaget Biotage har tecknat avtal om att förvärva brittiska Astrea Bioseperations i en affär värd över två miljarder kronor. Betalning sker i aktier ti...

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Så mycket väntas lecanemab sälja globalt

Försäljningen av Leqembi (lecanemab), som nyligen fick ett accelererat USA-godkännande som behandling mot Alzheimers sjukdom, väntas globalt uppgå till sju milj...

Ny ordförande för Atlas Antibodies

Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.

How critical are the “Spermageddon” reports? – Researchers call for action

A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...

Nanoparticles to help detect pulmonary disease

Nanoparticles behave in a certain way in the air. Using this knowledge, researchers at Lund University have developed a new measurement method for lung examinat...

Nocebo – the evil twin that makes you feel worse

The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden

No longer afraid of the dentist.

Teaching robot with piezo technology

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Ny Sverigechef till Boehringer Ingelheim

Australiensaren Paul Dunesky har arbetat inom Boehringer Ingelheim sedan 2013 – nu blir han Sverigechef.

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Product Specialist at Gradientech AB, Uppsala

“We should avoid surgery if we can”

Since February this year, she has been Scientific Director Life Science at the Karolinska Institutet. Life Science Sweden met Anna Martling for a talk about rol...

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm....

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Elicera develops CAR-T against solid tumours – may become the first in the world

in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Stort vetenskapsmöte igång i Life City